Metabrain Research

Poxel S.a.s.

Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Annick Audet

Christine G Charon

Micheline R Kergoat

Sophie N Raynal

Franck F Lepifre

Valerie Autier

Daniel Cravo

Didier Mesangeau

Jean-Denis Durand

Annick Arbellot De Vacqueur

Gersande R Lena

Denis Carniato

Johannes Gleitz

Gérard Moinet

Gérard Botton

Caroline Leriche

Valérie Autier

Lauren R Faveriel

The present invention concerns a tryptophan metabolite chosen from kynurenic acid, anthranilic acid, quinolinic acid, picolinic acid, quinaldic acid and the mixtures of same or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt of same, for use as a drug intended for increasing and/or maintaining muscle mass and/or strength in a mammal, and in particular intended for treating and/or preventing muscle atrophy in mammals and/or for promoting muscle growth in mammals doing exercise and aiming to increase muscle mass and/or quality and/or strength, for preventing the appearance of symptoms of sarcopenia or for rehabilitation following muscle loss and/or for improving recovery time after an intense physical effort.

Use of tryptophan metabolites for treating muscle atrophy

This invention relates to oxime and alkoxy derivatives of the general formula (I), or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof for use as a medicament for the treatment and/or prevention of muscle atrophy in mammals and/or for limiting muscular atrophy in mammals and/or to promote muscle growth in exercising mammals aimed at increasing muscle mass and quality, preventing the occurrence of symptoms of sarcopenia related to age or rehabilitation after a muscle loss, age-related muscle atrophy and/or the consequences of drug therapy and/or immobilization and/or cachexia.

Derivatives used in the treatment of muscle atrophy

The present invention relates to a thiophene derivative of the following general formula I or an enantiomer, diastereoisomer, hydrate, solvate, tautomer, racemic mixture or pharmaceutically acceptable salt thereof or to its use as a drug in particular intended for treating and/or preventing diabetes, its complications and/or associated pathologies, advantageously diabetes of type II and hyperglycemia.

Useful thiophene derivatives in the treatment of diabetes

The present invention relates to imidazopyridine derivatives of the following general formula I: and to their use as a drug, in particular in treating and/or preventing diabetes, its complications and/or associated pathologies.

Imidazopyridine derivatives useful in treating diabetes

The invention relates to a composition for use as a medicament comprising insulin in combination with at least one compound of formula (I) wherein the radicals Rto Rhave the meaning according to claim, and/or physiologically acceptable salts thereof. Another object of the invention concerns a pharmaceutical composition comprising as active ingredients effective amounts of insulin and at least one compound of formula (I), together with pharmaceutically tolerable adjuvants, for the prophylactic or therapeutic treatment and/or monitoring of physiological and/or pathological conditions that are associated with insulin resistance. The invention also relates to a pharmaceutical package comprising insulin in a first dosage unit and at least one compound of formula (I) in a second dosage unit.

Combination of insulin with triazine derivatives and its use for treating diabetes

Imidazole derivatives of formula (I): wherein R, R, R, A, V and W are as defined in the description,

Imidazole derivatives as fructose-1,6-bisphosphatase inhibitors and pharmaceutical compositions containing them

Combination of insulin with triazine derivatives

The present invention relates to novel benzimidazole-dihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, to processes for the preparation thereof and to the use thereof in therapy, especially for the treatment of diabetes.

Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same

Growing community of inventors

Leudeville, France

Annick Audet